title: Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
abstract: The activity of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine] dichloroplatinum(II)-complexes (1-PtCl2,R,S; 2-PtCl2, R,R/S,S; 3-PtCl2, R,R; 4-PtCl2, S,S) on several tumor models (MDA-MB 231 breast cancer cell line; P 388 leukemia, mouse; L 1210 leukemia, mouse; L 5222 leukemia, rat; Ehrlich ascites tumor, mouse--wildtype; cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.) is described. For comparison the analogous [1,2-bis(4-hydroxyphenyl)ethylendiamine]dichloroplatinum (II)-complexes (5-PtCl2, R, S; 6-PtCl2, R,R/S,S; 7-PtCl2, R,R; 8-PtCl2, S,S) and cisplatin are used. 1-PtCl2 to 4-PtCl2 (OH in 3,3'-positions) show their maximum antitumor effect at lower doses than 5-PtCl2 to 8-PtCl2 (OH in 4,4'-positions). 2-PtCl2 and 6-PtCl2 (R,R/S,S) are more active than 1-PtCl2 and 5-PtCl2 (R,S). 4-PtCl2 and 8-PtCl2 (S,S) are superior to 3-PtCl2 and 7-PtCl2 (R,R). On the L 5222 leukemia 2-PtCl2 (R,R/S,S), 4-PtCl2 (S,S) and 8-PtCl2 (S,S) markedly surpass cisplatin. Strong effects are produced by 2-PtCl2 to 4-PtCl2 on the Ehrlich ascites tumor (wildtype, cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.). The combination of 4-PtCl2 with cisplatin results in a weakly synergistic effect.
authors.forename: M
authors.initials: M
authors.lastname: Jennerwein
authors.forename: R
authors.initials: R
authors.lastname: Gust
authors.forename: R
authors.initials: R
authors.lastname: Müller
authors.forename: H
authors.initials: H
authors.lastname: Schönenberger
authors.forename: J
authors.initials: J
authors.lastname: Engel
authors.forename: M R
authors.initials: MR
authors.lastname: Berger
authors.forename: D
authors.initials: D
authors.lastname: Schmähl
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: R
authors.initials: R
authors.lastname: Osieka
authors.forename: G
authors.initials: G
authors.lastname: Atassi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy; D051379:Mice; D008811:Mice, Inbred DBA; D009944:Organoplatinum Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D013237:Stereoisomerism; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C059728:dichloro(1,2-bis(3-hydroxyphenyl)ethylenediamine)platinum II